Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy
| Autor: | Rebecca Clark-Snow, Dan Powers, Bernardo Leon Rapoport, Sujata Arora, Rudolph M. Navari |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Cancer Research
medicine.medical_specialty Cyclophosphamide Nausea medicine.drug_class medicine.medical_treatment cisplatin Rolapitant Gastroenterology neurokinin‐1 receptor antagonist 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine rolapitant Internal medicine Medicine Antiemetic chemotherapy‐induced nausea and vomiting Radiology Nuclear Medicine and imaging 030212 general & internal medicine RC254-282 Original Research anthracycline/cyclophosphamide Chemotherapy highly emetogenic chemotherapy moderately emetogenic chemotherapy business.industry Clinical Cancer Research Neoplasms. Tumors. Oncology. Including cancer and carcinogens nausea Carboplatin Oncology chemistry 030220 oncology & carcinogenesis carboplatin Vomiting medicine.symptom business medicine.drug Chemotherapy-induced nausea and vomiting |
| Zdroj: | Cancer Medicine, Vol 7, Iss 7, Pp 2943-2950 (2018) Cancer Medicine |
| ISSN: | 2045-7634 |
| DOI: | 10.1002/cam4.1560 |
| Popis: | Most patients receiving highly or moderately emetogenic chemotherapy experience chemotherapy‐induced nausea and vomiting without antiemetic prophylaxis. While neurokinin‐1 receptor antagonists (NK‐1RAs) effectively prevent emesis, their ability to prevent nausea has not been established. We evaluated the efficacy of the long‐acting NK‐1RA rolapitant in preventing chemotherapy‐induced nausea using post hoc analyses of data from 3 phase 3 trials. Patients were randomized to receive 180 mg oral rolapitant or placebo approximately 1‐2 hours before chemotherapy in combination with a 5‐hydroxytryptamine type 3 RA and dexamethasone. Nausea was assessed by visual analog scale during the acute (≤24 hours), delayed (>24‐120 hours), and overall (0‐120 hours) phases. Post hoc analyses by treatment group (rolapitant vs control) were performed on pooled data within patient subgroups receiving cisplatin‐based, carboplatin‐based, or anthracycline/cyclophosphamide (AC)‐based chemotherapy. In the cisplatin‐based chemotherapy group, significantly more patients receiving rolapitant than control reported no nausea (NN) in the overall (52.3% vs 41.7% [P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|